Silber-Sponsor RGCC
RGCC is the doorway to personalized treatment
RGCC was founded in 2004 by genetics pioneer Dr. Ioannis Papasotiriou with the goal of developing personalized treatment options for more effective cancer care. Driven by his belief that personalized medicine – tailored to a patient’s unique genetic profi le – is the key to better outcomes, this vision continues to drive everything we do. Our commitment extends to evolving personalized medicine through relentless research and innovation. Our experts continually strive to develop new diagnostic and therapeutic options for cancer.
Advancing precision medicine with liquid biopsies Liquid biopsies offer a groundbreaking alternative to traditional biopsies, transforming cancer testing and research. In contrast to traditional biopsies, which focus on a single, localized area of the body, liquid biopsies collect data from distant (metastatic) sites as well. This non-invasive approach provides a comprehensive view of cancer throughout the body, offering invaluable insights for precise diagnosis and personalized treatment planning.
Our work spans three sectors:
1. RGCC Tests
At RGCC, we offer a whole suite of advanced diagnostic tests to help:
- Produce personalized patient profiles for cancer treatment
- Detect early signs of developing cancer
- Monitor existing cancers
- Follow-up monitoring for possible cancer metastasis
RGCC leverages precision medicine with advanced liquid biopsy tests to analyze circulating tumor cells (CTCs) and associated biomarkers in the bloodstream. This approach reveals the genetic composition of the cancer and enables individualized treatment approaches.
2. RGCC Therapies
There is no one-size-fits all approach to treating chronic disease. Every patient and their disease is different and they will respond to treatment in their own unique way. Our team of multidisciplinary scientists combines groundbreaking research with bestin-class technology to develop targeted therapies to improve patient outcomes. The field of advanced therapy medicinal products (ATMPs) has enormous potential to fulfill previously unmet medical needs. Our dedicated team of scientists is actively working to turn this potential into reality, developing a range of ATMPs designed to effectively combat various chronic diseases, including cancer.
3. RGCC R&D
We focus on the development of innovative targeted anti-cancer therapies to tackle cancer cells more precisely and reduce side effects. Additionally, we are dedicated to discovering new biomarkers to enhance cancer diagnostics.
Using human cancer cells grown in classical and advanced threedimensional cultivation systems, we identify cancer-specific genesand protein expression patterns for further drug development and unveil cellular interactions in the tumor microenvironment.
RGCC is a global organization
RGCC is a global organization committed to providing exceptional service worldwide. In collaboration with our branch offi ces and trusted distributors, we ensure a broad-reaching network. Our head offi ce is based in Switzerland, and we operate state-of-the-art laboratory facilities across the globe.
Visit rgcc-international.com to learn more!
